A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus
出版年份 2021 全文链接
标题
A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus
作者
关键词
-
出版物
Scientific Reports
Volume 11, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-06-29
DOI
10.1038/s41598-021-92925-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
- (2019) Jennifer R Donnan et al. BMJ Open
- Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis
- (2019) Tadashi Toyama et al. DIABETES OBESITY & METABOLISM
- Effects of sodium‐glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta‐analysis of randomized controlled trials
- (2019) Jingli Lu et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections
- (2019) Chintan V. Dave et al. ANNALS OF INTERNAL MEDICINE
- Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus
- (2019) Miao Feng et al. MEDICINE
- Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in East Asians with Type 2 Diabetes: A Systematic Review and Meta-Analysis
- (2019) Lidan Yang et al. Diabetes Therapy
- Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial
- (2018) Ryuzo Kawamori et al. DIABETES OBESITY & METABOLISM
- Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial
- (2018) Akira Shimada et al. DIABETES OBESITY & METABOLISM
- Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials
- (2018) Tomohide Yamada et al. DIABETES OBESITY & METABOLISM
- The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis
- (2017) Jiao Chen et al. Scientific Reports
- Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus
- (2016) Nobuya Inagaki et al. Cardiovascular Diabetology
- Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus
- (2016) Masakazu Haneda et al. CLINICAL THERAPEUTICS
- Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials
- (2016) Dandan Li et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study
- (2016) Hisamitsu Ishihara et al. DIABETES OBESITY & METABOLISM
- Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials
- (2016) H. L. Tang et al. DIABETES OBESITY & METABOLISM
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period
- (2016) Eiichi Araki et al. Journal of Diabetes Investigation
- Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study
- (2015) Rimei Nishimura et al. Cardiovascular Diabetology
- A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long-Term ASP1941 Safety Evaluation in Patients with Type 2 Dia
- (2015) A. Kashiwagi et al. DIABETES OBESITY & METABOLISM
- Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
- (2015) B. Bode et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years
- (2015) Xiang-Yang Liu et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial
- (2014) Takashi Kadowaki et al. ADVANCES IN THERAPY
- Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
- (2014) Kohei Kaku et al. Cardiovascular Diabetology
- Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study
- (2014) Yutaka Seino et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study
- (2014) Yutaka Seino et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study
- (2014) Yutaka Seino et al. CURRENT MEDICAL RESEARCH AND OPINION
- Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study
- (2014) A. Kashiwagi et al. DIABETES OBESITY & METABOLISM
- Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea
- (2014) L. Ji et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study
- (2014) Nobuya Inagaki et al. EXPERT OPINION ON PHARMACOTHERAPY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2013) David Moher ANNALS OF INTERNAL MEDICINE
- Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study
- (2013) N. Inagaki et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials
- (2013) M. Monami et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
- (2013) J.-F. Yale et al. DIABETES OBESITY & METABOLISM
- Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
- (2013) Atsunori Kashiwagi et al. Journal of Diabetes Investigation
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started